Clinical Study on the Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab and S-1 in the Conversion Treatment of HER2 Overexpression Unresectable Gastric Cancer
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Disitamab vedotin (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Sintilimab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 20 Jan 2024 Status changed from not yet recruiting to recruiting.
- 20 Jan 2024 Trial design, presented at the 2024 Gastrointestinal Cancers Symposium
- 29 Nov 2022 New trial record